Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
Biomarkers, Breast Density And Risk Reduction Perspectives In BRCA Carriers
Sponsor: City of Hope Medical Center
Listed as NCT00080756, this PHASE2 trial focuses on Breast Cancer and brca1 Mutation Carrier and remains ongoing. Sponsored by City of Hope Medical Center, it has been updated 17 times since 2004, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
17 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 12 earlier versions
-
Dec 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- City of Hope Medical Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Duarte, United States